...
机译:人免疫缺陷病毒1型少数态变异对瑞培的一线第一线方案对病毒反应的影响
INSERM U1043 Toulouse France;
CHU Toulouse Lab Virol Toulouse France;
Hop Paul Brousse Lab Virol Villejuif France;
CHU Bordeaux Lab Virol Bordeaux France;
CHU Rennes Lab Virol Rennes France;
Hosp Civils Lyon Hop Croix Rousse Lab Virol Lyon France;
Hop St Antoine Lab Virol Paris France;
CHU Hotel Dieu Lab Virol Nantes France;
Hop Tenon Lab Virol Paris France;
CHU Rouen Lab Virol Rouen France;
CHU Lille Lab Virol Lille France;
CHU Poitiers Lab Virol Poitiers France;
Hop Henri Mondor Lab Virol Creteil France;
Hop La Pitie Salpetriere Lab Virol Paris France;
Univ Paris Diderot Hop Bichat Claude Bernard AP HP INSERM Sorbonne Paris Cite Lab Virol Infect;
CHU Nancy Lab Virol Nancy France;
CHU Clermont Ferrand Lab Virol Clermont Ferrand France;
CHU Caen Lab Virol Caen France;
CHU Angers Lab Virol Angers France;
Hop Versailles Lab Virol Le Chesnay France;
CHU Grenoble Lab Virol Grenoble France;
CHU Tours Lab Virol Tours France;
CHU Dijon Lab Virol Dijon France;
Hop Necker Enfants Malad Lab Virol Paris France;
CHU Amiens Lab Virol Amiens France;
Hop La Pitie Salpetriere Lab Virol Paris France;
INSERM U1043 Toulouse France;
Hop La Pitie Salpetriere Lab Virol Paris France;
Hop Henri Mondor Lab Virol Creteil France;
Univ Paris Diderot Hop Bichat Claude Bernard AP HP INSERM Sorbonne Paris Cite Lab Virol Infect;
INSERM U1043 Toulouse France;
minority resistant variants; rilpivirine; first-line antiretroviral therapy; ultra-deep sequencing;
机译:人免疫缺陷病毒1型少数态变异对瑞培的一线第一线方案对病毒反应的影响
机译:病毒进化和变异表位频率对人类免疫缺陷病毒1型特异性CD8〜+ T细胞反应的影响
机译:测定最近使用系统发育重建感染的人的人免疫缺陷病毒1型耐药少数症变异的起源
机译:通过使用LCX PCR系统测试,同时提取人免疫缺陷病毒类型1(HIV-1)和丙型肝炎病毒(HCV)RNA,不会损害两种病毒的病毒载量的测量
机译:使用腺病毒和腺伴随病毒载体的初免-加强疫苗策略诱导针对I型人免疫缺陷病毒的CD8 + T细胞应答
机译:Rilpivirine为基础的方案从基于Nevirapine的方案转用疗法在人类免疫缺陷病毒感染的病毒学抑制患者中的疗效:一项随机对照试验
机译:基于瑞潮的方案的疗效作为基于Neviropine的鼻制术病毒感染病毒抑制患者的Neviropine的方案的切换治疗:随机对照试验
机译:使用委内瑞拉马脑炎病毒(VEE)复制子系统诱导和表征小动物的免疫应答,表达人类免疫缺陷病毒1型(HIV-1)包膜基因